Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry

Ítems similars

• Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry
  per: Walker, Ulrich A, et al.
  Publicat: (2021)
• β-Confident-registry: aiming to be largest-ever studied cohort of cryopyrin-associated periodic syndromes (CAPS) patients. Study design and baseline characteristics
  per: Kuemmerle-Deschner, J, et al.
  Publicat: (2011)
• Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians
  per: Kuemmerle-Deschner, Jasmin B., et al.
  Publicat: (2013)
• Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry
  per: Tilson, Hugh, et al.
  Publicat: (2013)
• A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report
  per: Hansmann, Sandra, et al.
  Publicat: (2011)